(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

Delgocitinib cream had superior efficacy and a better safety profile compared with oral alitretinoin for the treatment of ...

April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to ...

The Food Safety and Drug Administration Department in Karnataka has flagged 97 out of 220 local ice cream and cool drink manufacturing units for selling substandard products under unhygienic ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best undervalued UK stocks to buy right now. The global markets entered 2025 in the hope that the ...

It is worth considering GSK (GSK), which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this drug developer has recorded a strong streak of ...